Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B10 | O60218 | 3/20 | 0.76 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.76 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.66 |
| ▸ | SHBG | P04278 | 3/20 | 0.66 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.66 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.66 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.66 |
| ▸ | PGR | P06401 | 1/20 | 0.66 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.66 |
| ▸ | AR | P10275 | 1/20 | 0.66 |
| ▸ | MGAM | O43451 | 1/20 | 0.66 |
| ▸ | G6PD | P11413 | 6/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9510938 | 1.00 | AKR1B10 (0.76) | AKR1B10AKR1B1GPBAR1CYP3A4SHBG | |
| SCHEMBL19584783 | 1.00 | AKR1B10 (0.76) | AKR1B10AKR1B1GPBAR1CYP3A4SHBG | |
| SCHEMBL23144727 | 1.00 | AKR1B10 (0.76) | AKR1B10AKR1B1GPBAR1CYP3A4SHBG | |
| SCHEMBL676328 | 1.00 | AKR1B10 (0.76) | AKR1B10AKR1B1GPBAR1CYP3A4SHBG | |
| SCHEMBL37778 | 0.86 | AKR1B10 (1.00) | AKR1B10AKR1B1GPBAR1CYP3A4SHBG | |
| SCHEMBL675417 | 0.86 | AKR1B10 (1.00) | AKR1B10AKR1B1GPBAR1CYP3A4SHBG | |
| SCHEMBL17776486 | 0.86 | AKR1B10 (1.00) | AKR1B10AKR1B1GPBAR1CYP3A4SHBG | |
| SCHEMBL12646116 | 0.86 | AKR1B10 (1.00) | AKR1B10AKR1B1GPBAR1CYP3A4SHBG | |
| SCHEMBL23699767 | 0.86 | AKR1B10 (1.00) | AKR1B10AKR1B1GPBAR1CYP3A4SHBG | |
| SCHEMBL19156379 | 0.86 | AKR1B10 (1.00) | AKR1B10AKR1B1GPBAR1CYP3A4SHBG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 554 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250032510-A1 | AMORPHOUS SOLID DISPERSION GANAXOLONE FORMULATION | IMMEDICA PHARMA US INC. | 2025-01-30 | — | — | US | claimed |
| US-20240197754-A1 | ANTICONVULSANT ACTIVITY OF STEROIDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-06-20 | — | — | US | claimed |
| US-20240099995-A1 | METHOD OF PREPARING A TOPICAL PHARMACEUTICAL COMPOSITION | PHEBRA PTY LTD (AU) | 2024-03-28 | — | — | US | claimed |
| EP-4291171-A1 | METHOD OF PREPARING A TOPICAL PHARMACEUTICAL COMPOSITION | Phebra Pty Ltd (AU) | 2023-12-20 | — | — | EP | claimed |
| US-20230183238-A1 | RING DEUTERATED GABOXADOL AND ITS USE FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | CERTEGO ABC, LLC | 2023-06-15 | — | — | US | claimed |
| WO-2023060067-A1 | AMORPHOUS SOLID DISPERSION GANAXOLONE FORMULATION | MARINUS PHARMACEUTICALS, INC. (US) | 2023-04-13 | — | — | WO | claimed |
| EP-4153549-A2 | RING DEUTERATED GABOXADOL AND ITS USE FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | Certego Therapeutics Inc. (US) | 2023-03-29 | — | — | EP | claimed |
| US-11597726-B2 | Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders | Certego Therapeutics Inc. (US) | 2023-03-07 | — | — | US | claimed |
| CN-114891756-A | Construction and application of aspergillus ochraceus steroid C11 alpha-hydroxylase CYP68J5 mutant | 天津科技大学 | 2022-08-12 | — | — | CN | claimed |
| US-20220127261-A1 | RING DEUTERATED GABOXADOL AND ITS USE FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | CERTEGO ABC, LLC | 2022-04-28 | — | — | US | claimed |
| EP-2178502-A2 | SUSTAINED DELIVERY OF DRUGS FROM BIODEGRADABLE POLYMERIC MICROPARTICLES | YALE UNIVERSITY (US) | 2010-04-28 | — | — | EP | claimed |
| WO-2010001391-A1 | DERMAL APPLICATION OF VASOCONSTRICTORS | ZACHAR ORON (IL) | 2010-01-07 | — | — | WO | claimed |
| WO-2008157614-A9 | SUSTAINED INTRAOCULAR DELIVERY OF DRUGS FROM BIODEGRADABLE POLYMERIC MICROPARTICLES | UNIV YALE (US) | 2009-03-26 | — | — | WO | claimed |
| WO-2008157614-A2 | SUSTAINED INTRAOCULAR DELIVERY OF DRUGS FROM BIODEGRADABLE POLYMERIC MICROPARTICLES | YALE UNIVERSITY (US) | 2008-12-24 | — | — | WO | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20050152957-A1 | Compositions and delivery systems for administration of a local anesthetic agent | CORIUM INTERNATIONAL (US) | 2005-07-14 | — | — | US | claimed |
| US-20030027833-A1 | Compositions and delivery systems for administration of a local anesthetic agent | CORIUM INTERNATIONAL, INC. | 2003-02-06 | — | — | US | claimed |
| WO-2002089849-A1 | COMPOSITIONS AND DELIVERY SYSTEMS FOR ADMINISTRATION OF A LOCAL ANESTHETIC AGENT | CORIUM INTERNATIONAL (US) | 2002-11-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240197754-A1 | ANTICONVULSANT ACTIVITY OF STEROIDS | CYP21A2, HSD3B1, HSD17B2 | AKR1B10 414/4885AKR1B1 318/4885GPBAR1 543/4885 |
| US-20230183238-A1 | RING DEUTERATED GABOXADOL AND ITS USE FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | GABRD, GABRA6, GABRA3 | AKR1B10 958/4885AKR1B1 1584/4885GPBAR1 562/4885 |
| US-20250032510-A1 | AMORPHOUS SOLID DISPERSION GANAXOLONE FORMULATION | PYGB, GYS2, CYP21A2 | AKR1B10 282/4885AKR1B1 942/4885GPBAR1 1711/4885 |
| US-20220127261-A1 | RING DEUTERATED GABOXADOL AND ITS USE FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | GABRD, GABRA6, GABRA3 | AKR1B10 958/4885AKR1B1 1584/4885GPBAR1 562/4885 |
| US-11597726-B2 | Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders | GABRD, GABRA6, GABRA3 | AKR1B10 958/4885AKR1B1 1584/4885GPBAR1 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.